PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-129.30%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
7.42%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
110.61%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
110.61%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
2444.00%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
2720.00%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2720.00%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
-0.03%
Reduced diluted shares while CVE is at 0.01%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-50.00%
Dividend reduction while CVE stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-48.46%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-58.78%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-188.26%
Negative 10Y revenue/share CAGR while CVE stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-146.64%
Negative 5Y CAGR while CVE stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-134.26%
Negative 3Y CAGR while CVE stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
266.04%
OCF/share CAGR of 266.04% while CVE is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
69.02%
OCF/share CAGR of 69.02% while CVE is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-1.09%
Negative 3Y OCF/share CAGR while CVE stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
771.98%
10Y net income/share CAGR of 771.98% while CVE is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
-61.67%
Negative 5Y net income/share CAGR while CVE is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
16.21%
3Y net income/share CAGR of 16.21% while CVE is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
346.73%
Equity/share CAGR of 346.73% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
80.64%
Equity/share CAGR of 80.64% while CVE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
14.39%
Equity/share CAGR of 14.39% while CVE is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
956.98%
Dividend/share CAGR of 956.98% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
405.76%
Dividend/share CAGR of 405.76% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
131.91%
3Y dividend/share CAGR of 131.91% while CVE is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-38.57%
Firm’s AR is declining while CVE shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-98.35%
Inventory is declining while CVE stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-36.14%
Negative asset growth while CVE invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-33.43%
We have a declining book value while CVE shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-45.47%
We’re deleveraging while CVE stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.